Hepatitis news and hepatitis widget

Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of the fourth cohort of a 4-week Phase 1 proof-of-concept clinical trial evaluating R7128 1500mg twice daily (BID) in combination with the standard of care (SOC), Pegasys(R) (pegylated interferon) plus Copegus(R) (ribavirin) in 20 patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 who had not achieved a Sustained Viral Response (SVR) with prior SOC therapy.

Caption: Natalie Cole outside Madeo restaurant Los Angeles, California .... NATALIE COLE is set to shave her head because radiation treatment is causing clumps of her hair to fall out.

The U.S. Food and Drug Administration today approved the first nucleic acid test for hepatitis B virus that measures the amount of viral DNA in a patient's blood.